Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Kinetically guided removal of plama pegylated liposomal doxorubicin to enhance the benefit of cytostatic therapy of patients with ovarian cancer.

Trial Profile

Kinetically guided removal of plama pegylated liposomal doxorubicin to enhance the benefit of cytostatic therapy of patients with ovarian cancer.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Mar 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doxorubicin liposomal (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 09 Mar 2016 Status changed from recruiting to completed as per European Clinical Trials Database record.
    • 11 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top